{"id":"NCT00775203","sponsor":"Labopharm Inc.","briefTitle":"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.","officialTitle":"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2008-10-20","resultsPosted":"2010-04-07","lastUpdate":"2012-04-27"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Trazodone Hydrochloride (HCl) Extended-Release Tablets","otherNames":["Oleptro"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Trazodone Contramid Once A Day (OAD)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Trazodone Contramid OAD","deltaMin":23.2,"sd":4.16},{"arm":"Placebo","deltaMin":22.4,"sd":4.43}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0119"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":28},"locations":{"siteCount":36,"countries":["United States","Canada"]},"refs":{"pmids":["19724732"],"seeAlso":["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15386"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":202},"commonTop":["Headache","Somnolence","Dry mouth","Dizziness","Nausea"]}}